32 results about "Manic Disorders" patented technology

The present invention is an improvement in the treatment of mania and depression by administering topiramate in a sustained-release formulation. The sustained-release formulation of the present invention may also be co-administered with anti-psychotics and anti-depressants.

The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.

The present invention relates to certain pharmaceutical compositions of a 5-HT2A serotonin receptor modulator and methods for preparing pharmaceutical composition related thereto. The pharmaceutical compositions are useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.

Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

The present invention relates to N-[(4-hydroxypiperidine-4- Base) methyl] pyridin-2 (1H)-one derivatives, their stereoisomers, their pharmaceutically acceptable salts and their solvates, and their preparation methods, and their use in the prevention or treatment of 5-HT system dysfunction Related central nervous system diseases such as depression, anxiety, cognitive deficits, mania, schizophrenia, pain, etc., or used as a tool drug to study 5-HT function and its 5-HT dysfunction related diseases, and pharmaceutical compositions containing these compounds. Each substituent in formula I is as described in the specification.

The invention features methods of treating mood disorders, such as manic disorders, and stabilizing moods by administering a kappa agonist or partial agonist to a subject in need thereof.

Methods and kits for assessing the susceptibility of a patient to antidepressant-induced mania are described. The method involves testing a sample from a patient for the presence of the s variant of the 5HTTLPR polymorphism in the 5HTT gene. The presence of this s variant indicates that the patient is more susceptible to antidepressant-induced mania.

The patent discloses long-term injectable formulations and delivery systems of cariprazine and related salts and derivatives in the prevention and treatment of various psychotic diseases, such as schizophrenia, mania, and bipolar disorder. The dosage forms are either microsphere, microparticle, nanoparticle drug delivery systems in a pharmaceutically acceptable carrier, or devices that contain long-term injectable formulation of such cariprazine and related salts and derivatives.

The invention discloses a preparation method and application of a compound 3-hydroxy-3',4'-dihydroxy-phenethyl butyrate as shown in a formula I in the specification, and particularly discloses a compound with a structure as shown in the formula I, and application of the compound as shown in the formula I, a mixture of optically pure isomers and enantiomers of the compound mixed in any ratio or pharmaceutically acceptable salts of the compound in preparation of health food and medicines for relieving brain fatigue and improving learning and memory abilities and mania symptoms.

The invention discloses a Chinese medicament preparation for treating daftness and a preparation method thereof, belonging to the field of Chinese medicaments. Effective components of the Chinese medicament preparation comprise raw materials including argy wormwood leaf, manyflower glorybower root, melaleuca leucadendra bark, greenish lily bulb, cynanchum thesioides, borneol, fructus piperis longi, wild aconite root, phellodendri, xanthium canadense, anemone clematis stem, resak lidi jenuong, alhagi pseudalhagi, medicament sweetflag rhizome, hemp spike and rice bean flower. The Chinese medicament preparation disclosed by the invention selects medicinal materials with appropriately compatibility, accords with the theories of the traditional Chinese medicine and pharmacy and the modern medicine and pharmacology, and has the effects of regulating qi and resolving depression, relieving palpitation and eliminating phlegm, quieting spirit and stabilizing mind and clearing liver and purging intense heat, has a significant curative effects on treating daftness, is short in courses of treatment, quick in action, safe, reliable and free of any toxic or side effects, can not cause relapse after curing, and is obvious in curative effects; according to clinical trials, the total effective rate can reach up to 98.2%.

The invention provides a medicine for treating mania. The medicine for treating the mania is prepared from the following raw materials: 15-30 parts of Chinese angelica roots, 30-60 parts of cassia twigs, 90-120 parts of white peony roots, 30-60 parts of fresh ginger, and 3-5 Chinese dates. The medicine for treating the mania is prepared from purely natural Chinese herbal medicines so that the medicine for treating the mania is natural, non-toxic and free of side effects; and moreover, the medicine for treating the mania is low in cost, easy to use and feasible to implement. In addition, the medicine for treating the mania can realize the functions of soothing the liver, clearing away heat, replenishing the blood, tonify Qi, suppressing hyperactive liver for calming endogenous wind, dispersing the liver, regulating Qi, tonifying the kidney, invigorating the spleen and the like under the synergistic effects of the medicinal components. It has been proven by many years of clinical application that the medicine for treating the mania provided by the invention has remarkable curative effects on the mania. The invention further provides a conditioning drug formulation for treating curedmania which can be used for strongly consolidating the treatment effects of the medicine so as to prevent the mania from relapsing.

The invention discloses a traditional Chinese medicine composition for treating schizophrenia and mania, and belongs to the technical field of traditional Chinese medicine compositions. Its composition in parts by weight is: Pinellia 10-15 parts, Gentiana 5-10 parts, Citrus aurantium 5-10 parts, buffalo horn 20-30 parts, Scutellaria baicalensis 5-10 parts, Trichosanthes 20-30 parts , 5-10 parts of Shichangpu, 10-15 parts of white peony root, 25-30 parts of radish seed, 5-10 parts of Dannan star, 5-10 parts of white mustard seed, 5-10 parts of poria cocos, 5-10 parts of tangerine peel, gardenia 5-10 parts, Angelica 5-10 parts, Licorice 5-10 parts, Gastrodia elata 10-15 parts, Suanzaoren 5-10 parts, Ophiopogon japonicus 10-15 parts, Rhubarb 10-15 parts, Ginger 10-15 parts. The traditional Chinese medicine composition has the advantages of fast onset of action, good therapeutic effect, and low risk of pathogenic obesity.

The invention belongs to the field of medicines, and particularly relates to application of heparin or a derivative thereof or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing or treating mental diseases. The mental diseases are preferably one or a combination of more than two of depression, mania, learning and memory ability disorder and insomnia, and are further preferably bipolar disorder. The heparin or the derivative thereof or the pharmaceutically acceptable salt thereof is prepared into a composition by a conventional preparation method, and / or is added with an emotion stabilizer to prepare a medicine composition; and the prepared product solves the technical problems that the bipolar disorder is complicated in condition, difficult to treat andeasy to repeatedly attack. The heparin has a significant two-way regulation effect on depressive attack and mania attack of the bipolar disorder, has the advantages of being small in toxic and side effects and capable of preventing repeated attack, and has a good prospect of being developed into a medicine for preventing and treating the bipolar disorder.

The invention discloses a 6H-1,3-oxazoline-6-one compound represented by a formula I, or pharmaceutically acceptable salt thereof. According to the present invention, the results of the in vitro influence on on norepinephrine content in rat brain tissues, the in-vivo young-stage SHR rat ADHD model open-field test, the influence of Y maze test, the physiological index detection, and the influence on rat brain tissue neuron damage repair show that the compound can well reduce the norepinephrine content in rat brain tissues, remarkably inhibit the hyperactivity of model rats, improve the learningand memory ability of model rats, and quickly and efficiently repair damaged cranial neurons, cannot affect the growth and the blood pressure of tested rats, and does not cause manic symptoms.

Disclosed herein are methods of administering relatively high doses of dexmedetomidine, or a pharmaceutically acceptable salt thereof, to a human subject without otherwise inducing significant sedation. The disclosed methods are particularly suitable for treating irritability, particularly when associated with neurodegenerative and / or neuropsychiatric disorders such as schizophrenia, bipolar disorders such as bipolar affective disorders or mania, dementia, depression, or delirium.

The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R1 is halogen or C1-C4 alkyl; and R2 and R3 are the same or different and represent hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, alkylthio, hydroxy, amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino, or R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.